The U.S. market for PD-1 inhibitors has entered a new phase of evolution. According to the latest RealTime Dynamix™: PD-1 Inhibition in ...
Oncologists have moved beyond evaluating subcutaneous PD-1 inhibitors as convenient alternatives to intravenous therapy, instead incorporating them into disease-specific treatment strategies as ...
SYNTECA BIO, an artificial intelligence (AI)-based drug development company, has secured a biobetter candidate with improved solubility over conventio ...
Keytruda now holds more than 40 FDA-approved indications spanning 19 tumor types. The drug has played an instrumental role in ...
The Patents Court has dismissed an application by Merck Sharp & Dohme (UK) Limited seeking further disclosure of experimental ...
Strong Buy on oncology pipeline gains and LIPFENDRA launch, with KEYTRUDA patent risks. Click for this MRK update.
Morning Overview on MSN
Regulators cleared Keytruda with chemo before and after surgery for aggressive bladder cancer
Adults diagnosed with muscle-invasive bladder cancer gained a new treatment option on July 10, 2026, when the FDA cleared the ...
FDA clears subcutaneous Sarclisa Escena for multiple myeloma, showing comparable overall response rates to IV delivery.
Merck (NYSE:MRK) received FDA approval for expanded use of Keytruda and Keytruda QLEX combinations with Padcev in ...
Merck's Keytruda in combination with Pfizer's Padcev wins FDA nod for expanded use in muscle-invasive bladder cancer, ...
Pembrolizumab plus enfortumab vedotin is now approved for all adults with muscle-invasive bladder cancer undergoing cystectomy.
The Food and Drug Administration approved a combination treatment by Merck & Co., Pfizer, and Astellas Pharma for a hard-to-treat form of bladder cancer. The agency greenlit Merck's Keytruda and its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results